EP2240188A1 - Salbe auf der basis eines dialysats aus kälberblut - Google Patents

Salbe auf der basis eines dialysats aus kälberblut

Info

Publication number
EP2240188A1
EP2240188A1 EP08706951A EP08706951A EP2240188A1 EP 2240188 A1 EP2240188 A1 EP 2240188A1 EP 08706951 A EP08706951 A EP 08706951A EP 08706951 A EP08706951 A EP 08706951A EP 2240188 A1 EP2240188 A1 EP 2240188A1
Authority
EP
European Patent Office
Prior art keywords
ointment
skin
alpha
delta
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08706951A
Other languages
English (en)
French (fr)
Other versions
EP2240188A4 (de
Inventor
Mohamed Hamdi Hasan Badrawi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2240188A1 publication Critical patent/EP2240188A1/de
Publication of EP2240188A4 publication Critical patent/EP2240188A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/678Tocopherol, i.e. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/983Blood, e.g. plasma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth

Definitions

  • Topical retinoid Derived from vitamin A, retinoid that you apply to the skin may be able to reduce fine wrinkles, splotchy pigmentation and skin roughness. Retinoid must be used with a skin-care program that includes sunscreen and protective clothing because the medication can make the skin bum more easily. It may also cause redness, dryness, itching, and a burning or tingling sensation.
  • Nonprescription wrinkle creams The effectiveness of anti-wrinkle creams depends in part on the active ingredient or ingredients. Retinol, alpha hydroxy acids, kinetin, coenzyme QlO, copper peptides and antioxidants may result in slight to modest improvements in wrinkles. Surgical procedures and other techniques
  • Microdermabrasion This technique is similar to dermabrasion, but less surface skin is removed. It's done using a vacuum suction over the face while aluminum oxide crystals essentially sandblast the skin. Microdermabrasion usually requires repeated treatments to maintain the subtle, temporary results.
  • Laser, light source and radio frequency treatments In laser resurfacing, a laser beam destroys the outer layer of skin (epidermis) and heats the underlying skin (dermis), which stimulates the growth of new collagen fibers. As the wound heals, new skin forms that's smoother and tighter. It can take up to several months to fully heal from laser resurfacing. Less intense lasers (nonablative lasers), pulsed light sources and radio frequency devices don't injure the epidermis. These treatments heat the dermis and cause new collagen and elastin formation. After several treatments, skin feels firmer and appears refreshed. This means shorter recovery times, but treatment typically needs to be repeated more often and results are subtle.
  • Botulinum toxin type A Botox
  • Botox When injected in small doses into specific muscles, Botox blocks the chemical signals that cause muscles to contract. When the muscles can't tighten, the skin flattens and appears smoother and less wrinkled. Botox works well on frown lines between the eyebrows and across the forehead, and crow's-feet at the corners of the eyes. Results typically last about three to four months. Repeat injections are needed to maintain results.
  • Soft tissue fillers which include fat, collagen and hyaluronic acid , can be injected into deeper wrinkles on your face. They plump and smooth out wrinkles and furrows and give the skin more volume. The procedure may need to be repeated every few months.
  • Face-lift The face-lift procedure involves removing excess skin and fat in the lower face and neck and tightening the underlying muscle and connective tissue. The results typically last five to 10 years. Healing times can be lengthy after a face-lift. Bruising and swelling are usually evident for two to three weeks after surgery.
  • A- Wrinkles are a natural part of aging, skin gets thinner, drier and less elastic. And it becomes less able to protect itself from damage. As a result, wrinkles, lines and creases form in the skin. Although genetics are the most important determiner of skin texture, a major contributor to wrinkles is spending too much time in the sun. Smoking also can negatively affect how the skin looks.
  • Wrinkles are caused by a combination of factors:
  • UV light Exposure to ultraviolet (UV) light.
  • UV light breaks down the skin's connective tissue — collagen and elastin fibers, which lie in the deeper layer of skin (dermis). Without the supportive connective tissue, the skin loses its strength and flexibility. As a result, skin begins to sag and wrinkle prematurely.
  • Smoking can accelerate the normal aging process of the skin, contributing to wrinkles. This may be due to changes in the blood supply to the skin around the lips.
  • B-A new ointment in two concentration composed of 70% Vaseline in oily solution (paraffin, almond oil, bees wax, perfume) as a base to which two substances were added:
  • Substance 1 vitamin E describes a family of eight antioxidants, four tocopherols, alpha-, beta-, gamma- and delta-, and four tocotrienols (also alpha-, beta-, gamma- and delta-).
  • Alpha-tocopherol is the only form of vitamin E that is actively maintained in the human body and is therefore, the form of vitamin E found in the largest quantities in the blood and tissue.
  • the fat-soluble vitamin, alpha-tocopherol is uniquely suited to intercepting free radicals and preventing a chain reaction of lipid destruction. Aside from maintaining the integrity of cell membranes throughout the body, alpha-tocopherol also protects the fats in low density lipoproteins (LDLs) from oxidation.
  • LDLs low density lipoproteins
  • Substance 2 Protein-free haemodialysate of calves' blood (Bos Taurus) chemically and biologically standardized 42.5 mg/ml. It is a tissue metabolism activator, chemically and biologically standardized - deproteinised, non antigenic and apyrogenic hemodialized extract form the blood of healthy young calf. It contains large amounts of natural low molecular weight substances - glycolipides, nucleosides, nucleotides, amino acids, oligopeptides, irreplaceable microelements, electrolytes, intervening products of carbohydrate and fat metabolism.
  • the low concentration SE CARE ointment has the ability of revitalize skin and abolishing skin wrinkling significantly
  • the high concentration SE CARE ointment has the ability to promote scalp hair growth and healing of persistent ulcers.
  • Ointment base (SE CARE) composed of 70% Vaseline in oily solution (paraffin, almond oil, bees wax, perfume) as a base to which two substances were added: a-Adding to every lOOgm of the base ointment 1 gm of substance 1 (vitaminE ⁇ and o. lgm of subtance2 (Protein-free haemodialysate of calves' blood (Bos Taurus) chemically and biologically standardized 42.5 mg/ml) a new ointment are created (SE CAREl) which when applied once daily on the skin has the ability to revitalize the skin and reduce the skin wrinkles significantly within three month.
  • SE CAREl composed of 70% Vaseline in oily solution (paraffin, almond oil, bees wax, perfume) as a base to which two substances were added: a-Adding to every lOOgm of the base ointment 1 gm of substance 1 (vitaminE ⁇ and o. lgm of subt
  • A-Ointment base (SE CARE) composed of 70% Vaseline in oily solution (paraffin, almond oil, bees wax, perfume) as a base to which two substances were added
  • B- substance 1 vitamin E describes a family of eight antioxidants, four tocopherols, alpha-, beta-, gamma- and delta-, and four tocotrienols (also alpha-, beta-, gamma- and delta-).
  • C- substance2 Protein-free haemodialysate of calves 1 blood (Bos Taurus) chemically and biologically standardized 42.5 mg/ml
  • Manufactured To Be Used as a topical treatment has the ability to revitalized the skin and reduce the skin wrinkles significantly, the ability to promote healing of persistent ulcer and to stimulate scalp hair growth.
EP08706951.4A 2008-01-30 2008-02-21 Salbe auf der basis eines dialysats aus kälberblut Withdrawn EP2240188A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2008010173 2008-01-30
PCT/EG2008/000010 WO2009095028A1 (en) 2008-01-30 2008-02-21 Ointment on the basis of a dialysate of calves' blood.

Publications (2)

Publication Number Publication Date
EP2240188A1 true EP2240188A1 (de) 2010-10-20
EP2240188A4 EP2240188A4 (de) 2013-05-01

Family

ID=40912296

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08706951.4A Withdrawn EP2240188A4 (de) 2008-01-30 2008-02-21 Salbe auf der basis eines dialysats aus kälberblut

Country Status (3)

Country Link
EP (1) EP2240188A4 (de)
JP (1) JP2011510935A (de)
WO (1) WO2009095028A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105456166A (zh) * 2015-12-21 2016-04-06 太仓张根木生物科技有限公司 一种抗皱保湿爽肤水

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63135309A (ja) * 1986-11-28 1988-06-07 Shiseido Co Ltd 皮膚外用剤
JPH0491009A (ja) * 1990-08-07 1992-03-24 Kanebo Ltd 皮膚化粧料
JPH06128138A (ja) * 1992-10-15 1994-05-10 Kyowa Hakko Kogyo Co Ltd 化粧料
US5486353A (en) * 1993-09-29 1996-01-23 Solco Basel Ag Antisun product
DE10156297A1 (de) * 2001-11-19 2003-05-28 Henkel Kgaa Mittel zum Schutz der Haut
US20040191196A1 (en) * 2002-12-16 2004-09-30 Dov Tamarkin Novel conjugate compounds and dermatological compositions thereof
US20060134046A1 (en) * 2004-12-21 2006-06-22 Ibrahim Hanna Skin nourishing and moisturizing cream

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757937A1 (de) * 1977-12-24 1979-06-28 Byk Gulden Lomberg Chem Fab Hautpflegemittel
DE3042999C2 (de) * 1980-11-14 1984-05-10 Solco Basel AG, Birsfelden Verfahren zur Herstellung eines Hautkosmetikums
DE4113346A1 (de) * 1991-04-24 1992-10-29 Lang Erich Zubereitung zur kraeftigung und regeneration des haarwuchses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63135309A (ja) * 1986-11-28 1988-06-07 Shiseido Co Ltd 皮膚外用剤
JPH0491009A (ja) * 1990-08-07 1992-03-24 Kanebo Ltd 皮膚化粧料
JPH06128138A (ja) * 1992-10-15 1994-05-10 Kyowa Hakko Kogyo Co Ltd 化粧料
US5486353A (en) * 1993-09-29 1996-01-23 Solco Basel Ag Antisun product
DE10156297A1 (de) * 2001-11-19 2003-05-28 Henkel Kgaa Mittel zum Schutz der Haut
US20040191196A1 (en) * 2002-12-16 2004-09-30 Dov Tamarkin Novel conjugate compounds and dermatological compositions thereof
US20060134046A1 (en) * 2004-12-21 2006-06-22 Ibrahim Hanna Skin nourishing and moisturizing cream

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Deite C.: "A Practical Treatise on the Manufacture of Perfumery:", , 1892, XP002694059, Philadelphia Retrieved from the Internet: URL:http://ia700504.us.archive.org/8/items/practicaltreatis00deitrich/practicaltreatis00deitrich.pdf [retrieved on 2013-03-14] *
See also references of WO2009095028A1 *

Also Published As

Publication number Publication date
JP2011510935A (ja) 2011-04-07
WO2009095028A1 (en) 2009-08-06
EP2240188A4 (de) 2013-05-01

Similar Documents

Publication Publication Date Title
Farris Topical vitamin C: a useful agent for treating photoaging and other dermatologic conditions
Ehrlich et al. Improvement in the appearance of wrinkles with topical transforming growth factor β1 and L-ascorbic acid
TW200412992A (en) Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto
GB2451224A (en) Cosmetic composition comprising an exfoliant, astringent, antioxidant and moisturiser
KR100673044B1 (ko) 경피 투여용 국소 조성물
KR20190013101A (ko) 흉터의 예방 또는 치료를 위한 조성물
CN113645985A (zh) 用于治疗性皮肤处理的方法、组合物、片材
US20110166222A1 (en) Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same
KR20170130742A (ko) 피부 재생용 화장품 조성물
US20130202540A1 (en) Method for repair of acute and chronic injury, such as burned and photodamaged skin
Fibrich et al. Fighting the inevitable: skin aging and plants
WO2009095028A1 (en) Ointment on the basis of a dialysate of calves' blood.
CN113693966B (zh) 一种美白淡斑亮采霜及其制备方法
Mohan et al. Dermaroller in dermatology and cosmetology
RU2352329C1 (ru) Способ лечения возрастных и косметических дефектов кожи лица
da Mota Silveira et al. Synergistic therapy for skin aging: The association of the microneedling technique and vitamin C from the point of view of orofacial harmonization
US8969411B2 (en) Vitamin C composition for use in the prevention and treatment of stretch other skin conditions and methods of using the same
KR20130017871A (ko) 리놀렌산을 유효성분으로 포함하는 백반증 치료용 화장품 조성물
RU2325900C2 (ru) Состав для кожи наружного применения
Singh-Behl et al. Chemical peels
De Padova et al. Biorevitalization and combination techniques
TWI664973B (zh) 荷葉萃取物用於治療色素沉積綜合症之用途
Fernandes Evolution of cosmeceuticals and their application to skin disorders, including aging and blemishes
KR20200056366A (ko) 흉터의 예방 또는 치료를 위한 조성물
CN116035997A (zh) 一种纯天然祛斑美白液的配制工艺及使用方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100728

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61Q 7/00 20060101ALI20130321BHEP

Ipc: A61K 8/98 20060101ALI20130321BHEP

Ipc: A61K 31/355 20060101ALI20130321BHEP

Ipc: A61Q 19/08 20060101ALI20130321BHEP

Ipc: A61K 35/14 20060101AFI20130321BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130403

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130903